Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Argilés G[au]:

Search results

Items: 41

1.

Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses.

Lenz HJ, Argiles G, Yoshino T, Lonardi S, Falcone A, Limón ML, Sobrero A, Hastedt C, Peil B, Voss F, Griebsch I, Van Cutsem E.

Clin Colorectal Cancer. 2019 Sep 4. pii: S1533-0028(18)30525-5. doi: 10.1016/j.clcc.2019.08.005. [Epub ahead of print]

2.

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.

Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A.

Mol Oncol. 2019 Sep;13(9):1827-1835. doi: 10.1002/1878-0261.12547. Epub 2019 Jul 31.

3.

Maximising clinical benefit with adequate patient management beyond the second line in mCRC.

Argiles G, Arnold D, Prager G, Sobrero AF, Van Cutsem E.

ESMO Open. 2019 May 13;4(2):e000495. doi: 10.1136/esmoopen-2019-000495. eCollection 2019. Review.

4.

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators.

Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.

PMID:
31003911
5.

Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials.

Matos I, Noguerido A, Ros J, Mulet N, Argilés G, Elez É, Tabernero J.

Expert Opin Investig Drugs. 2019 May;28(5):463-471. doi: 10.1080/13543784.2019.1599860. Epub 2019 Apr 20. Review.

PMID:
30905200
6.

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.

Argilés G, André T, Hollebecque A, Calvo A, Dahan L, Cervantes A, Leger C, Amellal N, Fougeray R, Tabernero J.

Eur J Cancer. 2019 May;112:12-19. doi: 10.1016/j.ejca.2019.01.101. Epub 2019 Mar 16.

PMID:
30889492
7.

First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.

Elez E, Gomez-Roca C, Soto Matos-Pita A, Argiles G, Valentin T, Coronado C, Iglesias J, Macarulla T, Betrian S, Fudio S, Zaragoza K, Tabernero J, Delord JP.

Invest New Drugs. 2019 Aug;37(4):674-683. doi: 10.1007/s10637-018-0674-x. Epub 2018 Nov 9.

PMID:
30411218
8.

Transcriptional subtyping and CD8 immunohistochemistry identifies poor prognosis stage II/III colorectal cancer patients who benefit from adjuvant chemotherapy.

Allen WL, Dunne PD, McDade S, Scanlon E, Loughrey M, Coleman H, McCann C, McLaughlin K, Nemeth Z, Syed N, Jithesh P, Arthur K, Wilson R, Coyle V, McArt D, Murray GI, Samuel L, Nuciforo P, Jimenez J, Argiles G, Dienstmann R, Tabernero J, Messerini L, Nobili S, Mini E, Sheahan K, Ryan E, Johnston PG, Van Schaeybroeck S, Lawler M, Longley DB.

JCO Precis Oncol. 2018 Jun 13;2018. doi: 10.1200/PO.17.00241.

9.

The safety of ramucirumab for the treatment of colorectal cancer.

Noguerido A, Mulet-Margalef N, Matos I, Ros J, Argilés G, Élez E, Tabernero J.

Expert Opin Drug Saf. 2018 Sep;17(9):945-951. doi: 10.1080/14740338.2018.1506762. Epub 2018 Aug 16. Review.

PMID:
30073902
10.

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.

Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limón ML, Saunders M, Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F, Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G.

Ann Oncol. 2018 Sep 1;29(9):1955-1963. doi: 10.1093/annonc/mdy241.

11.

TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.

Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG.

J Clin Invest. 2018 Aug 31;128(9):3887-3905. doi: 10.1172/JCI96393. Epub 2018 Aug 6.

12.

Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer.

Argiles G.

ESMO Open. 2018 May 20;3(4):e000377. doi: 10.1136/esmoopen-2018-000377. eCollection 2018. No abstract available.

13.

Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.

Mulet N, Matos I, Noguerido A, Martini G, Élez ME, Argilés G, Tabernero J.

Expert Opin Pharmacother. 2018 Apr;19(6):623-629. doi: 10.1080/14656566.2018.1453497. Epub 2018 Mar 28.

PMID:
29537896
14.

ESMO Leaders Generation Programme: an alumni insight.

Arruda LM, Criscitiello C, Lambertini M, Argiles G.

ESMO Open. 2018 Jan 29;3(1):e000312. doi: 10.1136/esmoopen-2017-000312. eCollection 2018. No abstract available.

15.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J.

JAMA Oncol. 2018 Apr 12;4(4):e175245. doi: 10.1001/jamaoncol.2017.5245. Epub 2018 Apr 12. Erratum in: JAMA Oncol. 2019 May 1;5(5):745.

16.

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer.

Prager G, Argilés G.

ESMO Open. 2017 Jul 29;2(3):e000205. doi: 10.1136/esmoopen-2017-000205. eCollection 2017. No abstract available.

17.

BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.

Sanz-Garcia E, Argiles G, Elez E, Tabernero J.

Ann Oncol. 2017 Nov 1;28(11):2648-2657. doi: 10.1093/annonc/mdx401. Review.

PMID:
29045527
18.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H.

Oncologist. 2017 Oct;22(10):1281. doi: 10.1634/theoncologist.2016-0133erratum. No abstract available.

19.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M, Barone C, Bouché O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S.

ESMO Open. 2017 Feb 13;1(6):e000111. doi: 10.1136/esmoopen-2016-000111. eCollection 2016.

20.

Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.

Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J.

Mol Oncol. 2017 Sep;11(9):1263-1272. doi: 10.1002/1878-0261.12099. Epub 2017 Jul 20.

21.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H.

Oncologist. 2017 Apr;22(4):375-e30. doi: 10.1634/theoncologist.2016-0133. Epub 2017 Mar 8. Erratum in: Oncologist. 2017 Oct;22(10 ):1281.

22.

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).

Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M.

ESMO Open. 2016 Dec 7;1(6):e000107. doi: 10.1136/esmoopen-2016-000107. eCollection 2016. Review.

23.

Unveiling changes in the landscape of patient populations in cancer early drug development.

Hierro C, Azaro A, Argilés G, Elez E, Gómez P, Carles J, Rodon J.

Oncotarget. 2017 Feb 21;8(8):14158-14172. doi: 10.18632/oncotarget.13258. Review.

24.

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.

Longo-Muñoz F, Argiles G, Tabernero J, Cervantes A, Gravalos C, Pericay C, Gil-Calle S, Mizuguchi H, Carrato-Mena A, Limón ML, Garcia-Carbonero R.

Clin Transl Oncol. 2017 Feb;19(2):227-235. doi: 10.1007/s12094-016-1528-7. Epub 2016 Jul 21.

25.

Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.

Sartore-Bianchi A, Loupakis F, Argilés G, Prager GW.

Ann Oncol. 2016 Aug;27(8):1456-66. doi: 10.1093/annonc/mdw191. Epub 2016 May 6. Review.

PMID:
27154421
26.

Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.

Azuara D, Santos C, Lopez-Doriga A, Grasselli J, Nadal M, Sanjuan X, Marin F, Vidal J, Montal R, Moreno V, Bellosillo B, Argiles G, Elez E, Dienstmann R, Montagut C, Tabernero J, Capellá G, Salazar R.

Mol Cancer Ther. 2016 May;15(5):1106-12. doi: 10.1158/1535-7163.MCT-15-0820. Epub 2016 Apr 1.

27.

The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.

Sánchez-Martín FJ, Bellosillo B, Gelabert-Baldrich M, Dalmases A, Cañadas I, Vidal J, Martinez A, Argilés G, Siravegna G, Arena S, Koefoed K, Visa L, Arpí O, Horak ID, Iglesias M, Stroh C, Kragh M, Rovira A, Albanell J, Tabernero J, Bardelli A, Montagut C.

Clin Cancer Res. 2016 Jul 1;22(13):3260-7. doi: 10.1158/1078-0432.CCR-15-2400. Epub 2016 Feb 17.

28.

Current and advancing treatments for metastatic colorectal cancer.

Sanz-Garcia E, Grasselli J, Argiles G, Elez ME, Tabernero J.

Expert Opin Biol Ther. 2016;16(1):93-110. doi: 10.1517/14712598.2016.1108405. Epub 2015 Nov 7. Review.

PMID:
26549053
29.

First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.

Elez E, Argilés G, Tabernero J.

Curr Treat Options Oncol. 2015 Nov;16(11):52. doi: 10.1007/s11864-015-0369-x. Review.

PMID:
26374340
30.

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.

García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Tabernero J, Scaltriti M, Baselga J, Serra V.

Clin Cancer Res. 2015 Dec 15;21(24):5499-5510. doi: 10.1158/1078-0432.CCR-14-3091. Epub 2015 Aug 13. Erratum in: Clin Cancer Res. 2016 Aug 1;22(15):3982.

31.

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.

Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG.

Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081. Epub 2015 Jul 29.

32.

Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.

Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S.

Eur J Cancer. 2015 Sep;51(14):1865-73. doi: 10.1016/j.ejca.2015.06.115. Epub 2015 Jul 18.

33.

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.

Gupta S, Argilés G, Munster PN, Hollebecque A, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Piha-Paul SA.

Clin Cancer Res. 2015 Dec 1;21(23):5235-44. doi: 10.1158/1078-0432.CCR-15-0180. Epub 2015 Jul 17.

34.

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer.

Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J.

Cancer Discov. 2015 Jun;5(6):598-609. doi: 10.1158/2159-8290.CD-14-1432. Epub 2015 May 11.

35.

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

Argilés G, Saunders MP, Rivera F, Sobrero A, Benson A 3rd, Guillén Ponce C, Cascinu S, Van Cutsem E, Macpherson IR, Strumberg D, Köhne CH, Zalcberg J, Wagner A, Luigi Garosi V, Grunert J, Tabernero J, Ciardiello F.

Eur J Cancer. 2015 May;51(8):942-9. doi: 10.1016/j.ejca.2015.02.013. Epub 2015 Mar 25.

PMID:
25818084
36.

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer.

Sastre J, Argilés G, Benavides M, Feliú J, García-Alfonso P, García-Carbonero R, Grávalos C, Guillén-Ponce C, Martínez-Villacampa M, Pericay C.

Clin Transl Oncol. 2014 Nov;16(11):942-53. doi: 10.1007/s12094-014-1212-8. Epub 2014 Sep 16. Review.

37.

A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells.

Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argilés G, Vivancos A, Tabernero J, Rojas S, Palmer HG.

Clin Cancer Res. 2013 Dec 15;19(24):6787-801. doi: 10.1158/1078-0432.CCR-12-1740. Epub 2013 Oct 29.

38.

Depicting the evolving scenario of translational-guided drug development.

Argilés G, Rodon J, Tabernero J.

Clin Transl Oncol. 2012 Dec;14(12):881-2. doi: 10.1007/s12094-012-0969-x. Epub 2012 Nov 13. No abstract available.

PMID:
23150220
39.

[Neuroendocrine tumors: the age of targeted therapies].

Capdevila J, Argilés G, Mulet-Margalef N, Tabernero J.

Endocrinol Nutr. 2012 Aug-Sep;59(7):438-51. Epub 2012 May 6. Review. Spanish.

PMID:
22565119
40.

Panitumumab: a summary of clinical development in colorectal cancer and future directions.

Argiles G, Dienstmann R, Elez E, Tabernero J.

Future Oncol. 2012 Apr;8(4):373-89. doi: 10.2217/fon.12.20. Review.

PMID:
22515440
41.

New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.

Capdevila J, Argiles G, Rodriguez-Frexinos V, Nuñez I, Tabernero J.

Discov Med. 2010 Feb;9(45):153-62. Review.

Supplemental Content

Loading ...
Support Center